Skip to main content

Table 2 Patient disposition and treatment exposure (safety population)

From: Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

  Bortezomib-rituximab (N=102) Rituximab (N=98)
Median number of cycles, n (range) 5 (1–5) 5 (1–5)
Median treatment duration, weeks (range) 25 (5–33) 25 (5–27)
Patients completing all 5 cycles, n (%) 65 (64) 52 (53)
Patients discontinuing prior to completing 5 cycles, n (%), due to: 37 (36) 46 (47)
Disease progression 26 (25) 38 (39)
AEs 8 (8) 2 (2)
Treatment-related 6 (6) 0
Death 1 (1) 1 (1)
Patient choice 2 (2) 4 (4)
Other reasons 0 1 (1)
Mean rituximab relative dose intensity, % 98 96
Mean bortezomib relative dose intensity, % 90 NA
  1. AEs, adverse events; NA, not applicable.